ReviewClinical cancer research : an official journal of the American Association for Cancer Research2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.Gynecologic oncology · 2023Trial
- Progress and challenges in expanding access to clinical trials in pancreatic cancer.Communications medicine · 2026Review
- How exclusion criteria can hinder eligibility for lung cancer studies among different racial and ethnic groups.PLOS digital health · 2026Article
- ICTIS: A Novel Scoring System to Assess the Inclusivity of Advanced NSCLC Immunotherapy Trials.JTO clinical and research reports · 2025Article
- Five Data-Informed Principles for Advancing Inclusive Research in Clinical Trials: A Pharma Perspective.Advances in therapy · 2025Article
- Effect of pretreatment lab abnormalities on the time-to-treatment discontinuation and overall survival of metastatic breast cancer patients receiving CDK 4/6i, PI3Ki, and/or mTORi.Breast cancer research and treatment · 2025Article
- Association of Community-Level Social Vulnerability With Clinical Trial Discussion and Participation Among Cancer Survivors.JCO oncology practice · 2025Article
- Centralized daily drug management in clinical trial institutions and specific implementation plans.Frontiers in drug safety and regulation · 2025Review
- Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort.Neuro-oncology · 2024Article
- Addressing disparities in cancer clinical trials: a roadmap to more equitable accrual.Frontiers in health services · 2024Article
- Evolving a national clinical trials learning health system.Learning health systems · 2023Article
- Call to action: overcoming enrollment disparities in cancer clinical trials with modernized eligibility criteria.JNCI cancer spectrum · 2023Article
- ELaPro, a LOINC-mapped core dataset for top laboratory procedures of eligibility screening for clinical trials.BMC medical research methodology · 2022Article
- Advancing Inclusive Research: Establishing Collaborative Strategies to Improve Diversity in Clinical Trials.Ethnicity & diseaseArticle
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
Abstract
purposeIn clinical research, eligibility criteria promote patient safety and optimize the evidence generated from clinical trials. However, overly stringent eligibility criteria, including laboratory requirements, may limit enrollment, resulting in delayed trial completion and potentially limiting applicability of trial results to a general practice population. EXPERIMENTAL
designStarting in 2018, a working group consisting of experts in direct patient care, the FDA, industry, and patient advocacy developed recommendations to guide the optimal use of laboratory reference ranges and testing intervals in clinical trial eligibility criteria and study procedures. The working group evaluated current eligibility criteria across different clinical trial phases and performed a literature review to evaluate the impact of and justification for laboratory test eligibility requirements and testing intervals in clinical trials. Recommendations were developed on the basis of the goals of promoting safety and optimizing the evidence generated, while also expanding eligibility and applicability, and minimizing excess burden of trial participation.
resultsIn general, we found little variation over time and trial phase in laboratory test requirements, suggesting that these eligibility criteria are not refined according to ongoing clinical experience. We propose recommendations to optimize the use of laboratory tests when considering eligibility criteria.
conclusionsTailoring the use of laboratory test requirements and testing intervals may increase the number and diversity of patients in clinical trials and provide clinical data that more closely represent the general practice populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.